echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Caring for a bright future, the establishment and introduction of mouse models of hereditary ophthalmic diseases

    Caring for a bright future, the establishment and introduction of mouse models of hereditary ophthalmic diseases

    • Last Update: 2022-09-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In 2017, Luxturna, the first gene therapy for the treatment of hereditary retinal dystrophy, was approved by the FDA to target inherited Retinal Diseases (IRDs)


    Vision "stolen" by time – a mouse model of neovascular macular degeneration (AMD).



    Figure 1 Schematic diagram of hVEGF overexpressed mouse (TG) construction strategy


    Figure 2 FFA (fundus fluorescence angiography) results





    Saeye Bio Ophthalmic Gene Therapy Solutions



    I sincerely hope that with the efforts of all parties, more gene therapy methods will enter clinical trials to help people with congenital blindness see the dawn


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.